Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
dimetindene (dimetindene maleate)
Novartis Consumer Health S.A.
dimetindene (dimetindene maleate)
1mg/g
gel
OTC
Global Drug Regulatory Affairs Fenistil® Gel Dimethindene maleate 0.1 % Novartis Consumer Health SA CH-1260 Nyon, Switzerland SUMMARY OF PRODUCT CHARACTERISTICS Author: Alain Bossy Document type: Core SPC Document status: Final Release date: June 26, 2001, supersedes version of August 24, 1995 Number of pages: 14 Property of Novartis Consumer Health SA Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Consumer Health SA Novartis Consumer Health SA CONFIDENTIAL Page 2 Summary of Product Characteristics Fenistil Gel CONTENTS 1. NAME OF THE MEDICINAL PRODUCT ................................................................ 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ....................................... 3 3. PHARMACEUTICAL FORM .................................................................................... 3 4. CLINICAL PARTICULARS ...................................................................................... 3 4.1. Therapeutic indications .................................................................................... 3 4.2. Posology and method of administration ............................................................ 3 4.3. Contra-indications............................................................................................ 3 4.4. Special warnings and special precautions for use .............................................. 3 4.5. Interactions with other medicinal products and other forms of interaction ......... 3 4.6. Pregnancy and lactation ................................................................................... 3 4.7. Effects on ability to drive and use machines...................................................... 4 4.8. Undesirable effects........................................................................................... 4 4.9. Overdose ......................................................................................................... 4 5. PHARMACOLOGICAL PROPERTIES ............................. Read the complete document